Chemistry42

Starting tomorrow! 📅 Cancer remains a global challenge, but the convergence of #AI and #healthcare offers unprecedented hope. At Google Cloud’s inaugural AI cancer event, we're bringing together the brightest minds in healthcare, technology, and public policy to explore the transformative potential of AI in revolutionizing #cancercare. Join Dr. Petrina Kamya, Ph.D., during the "AI-Powered Drug Discovery with AlphaFold" presentation tomorrow, at 11:05 am at the Boston Center for the Arts. For the full event details, please visit: https://bit.ly/4hqbUit #BostonAI #BostonBiotech #GoogleCloud Insilico Medicine

🛎 One month countdown! Hear from the scientific experts behind the Pharma.ai platform (https://pharma.ai/) a commercially-available end-to-end #generativeAl software and robotics platform designed to improve the quality and productivity of #pharmaceuticalresearch. You will hear new feature announcements and see how cutting-edge AI is transforming #drugdiscovery and research across the following platforms: -PandaOmics -Science42: DORA -Chemistry42 -Generative Biologics Secure your spot here before the webinar fills up! https://bit.ly/3AacyQw (Or, scan the image to register today!) We hope to see you in November.

📽 Get a look at the four applications available within the #Chemistry42 platform. They include: -#GenerativeChemistry -#Alchemistry -ADMET Profiling -Golden Cubes Chemistry42 is a comprehensive #smallmolecules drug discovery platform. It streamlines hit identification, hit-to-lead, and lead optimization programs. See how it can help expand your research needs today: https://lnkd.in/ePQcTM2D #DrugDiscovery #GenerativeAI

🔔 Announcing the latest nach0-pc updates from #Chemistry42 nach0-pc: Multi-task Language Model with Molecular Point Cloud Encoder (https://lnkd.in/d848_HVU) Recent advancements have integrated Language Models (LMs) into a drug discovery pipeline. However, existing models mostly work with SMILES and SELFIES chemical string representations, which lack spatial features vital for drug discovery. Additionally, attempts to translate chemical 3D structures into text format encounter issues such as excessive length and insufficient atom connectivity information. To address these issues, we introduce nach0-pc, a model combining domain-specific encoder and textual representation to handle spatial arrangement of atoms effectively. Our approach utilizes a molecular point cloud encoder for concise and order-invariant structure representation. We introduce a novel pre-training scheme for molecular point clouds to distillate the knowledge from spatial molecular structures datasets. After fine-tuning within both single-task and multi-task frameworks, nach0-pc demonstrates performance comparable with other diffusion models in terms of generated samples quality across several established spatial molecular generation tasks. Notably, our model is a multi-task approach, in contrast to diffusion models being limited to single tasks. Additionally, it is capable of processing point cloud-related data, which language models are not capable of handling due to memory limitations. These lead to our model having reduced training and inference time while maintaining on par performance. For the full paper, please visit: https://lnkd.in/d848_HVU #AIinDrugDiscovery #MolecularOptimization #MachineLearning #Research #DrugDevelopment #Innovation Insilico Medicine

🎤 Don't miss out on the latest updates, now available with Science42: #DORA See the latest updates here: https://pharma.ai/dora

Jensen Huang, the CEO of NVIDIA, generously offered his congratulations to the launch of Insilico's Pharma.AI platform. He remarked that "Insilico is at the forefront of the digital biology revolution." We do not take this recognition for granted. At Insilico Medicine, we remain steadfast in our commitment to innovation, always pursuing the latest technologies that could be applied to drug development, such as quantum computing, humanoid robotics, and large-scale automation. In the words of 2013 Nobel Laureate in Chemistry, Michael Levitt: "I want a society where everybody has self-worth, who feels good about themselves and feels good about other people. And I think AI has the option of doing that." We believe in a world where everyone on the planet has the right to quality healthcare. #DigitalBiology #AI #DrugDiscovery #Innovation #Healthcare #QuantumComputing #Robotics #Automation #InsilicoMedicine #PharmaAI #Nvidia #QualityHealthcare

#GenerativeAI can be used for #novelchemistry for aging research, #longevity, new materials, and so much more. Listen below 👇 Thank you to the team at GITEX GLOBAL Largest Tech & Startup Show in the World.

✈️Announcing Pharma AI Webinar Week https://bit.ly/4dL9lVo, coming this November! From November 19 - 21, get exclusive insights into our AI-powered platforms including PandaOmics, Chemistry42, Science42: DORA, and Generative Biologics. Discover how cutting-edge AI is transforming drug discovery and research! Secure your spot early, and stay tuned for more announcements! https://bit.ly/4f1NYzY #ProductLaunch #NewFeatures #PharmaAI #platforms

Save the date for Chemindix2024!

Jensen Huang, the CEO of NVIDIA, generously offered his congratulations to the launch of Insilico's Pharma.AI platform. He remarked that "Insilico is at the forefront of the digital biology revolution." We do not take this recognition for granted. At Insilico Medicine, we remain steadfast in our commitment to innovation, always pursuing the latest technologies that could be applied to drug development, such as quantum computing, humanoid robotics, and large-scale automation. In the words of 2013 Nobel Laureate in Chemistry, Michael Levitt: "I want a society where everybody has self-worth, who feels good about themselves and feels good about other people. And I think AI has the option of doing that." We believe in a world where everyone on the planet has the right to quality healthcare. #DigitalBiology #AI #DrugDiscovery #Innovation #Healthcare #QuantumComputing #Robotics #Automation #InsilicoMedicine #PharmaAI #Nvidia #QualityHealthcare